ATE339957T1 - Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs - Google Patents

Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs

Info

Publication number
ATE339957T1
ATE339957T1 AT00973002T AT00973002T ATE339957T1 AT E339957 T1 ATE339957 T1 AT E339957T1 AT 00973002 T AT00973002 T AT 00973002T AT 00973002 T AT00973002 T AT 00973002T AT E339957 T1 ATE339957 T1 AT E339957T1
Authority
AT
Austria
Prior art keywords
breast cancer
tyrosine kinase
egfr tyrosine
kinase inhibitors
treat breast
Prior art date
Application number
AT00973002T
Other languages
English (en)
Inventor
Nigel James Bundred
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester filed Critical Univ Manchester
Application granted granted Critical
Publication of ATE339957T1 publication Critical patent/ATE339957T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00973002T 1999-11-02 2000-11-01 Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs ATE339957T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9925958.2A GB9925958D0 (en) 1999-11-02 1999-11-02 Therapeutic use

Publications (1)

Publication Number Publication Date
ATE339957T1 true ATE339957T1 (de) 2006-10-15

Family

ID=10863835

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00973002T ATE339957T1 (de) 1999-11-02 2000-11-01 Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs

Country Status (21)

Country Link
US (1) US7553815B1 (de)
EP (1) EP1272188B1 (de)
JP (1) JP2003513035A (de)
KR (1) KR100785359B1 (de)
CN (1) CN1197577C (de)
AT (1) ATE339957T1 (de)
AU (1) AU779190B2 (de)
BR (1) BR0015194A (de)
CA (1) CA2389411C (de)
CY (1) CY1106285T1 (de)
DE (1) DE60030889T2 (de)
DK (1) DK1272188T3 (de)
ES (1) ES2275556T3 (de)
GB (1) GB9925958D0 (de)
IL (1) IL149176A0 (de)
MX (1) MXPA02004272A (de)
NO (1) NO323206B1 (de)
NZ (1) NZ518696A (de)
PT (1) PT1272188E (de)
WO (1) WO2001032155A2 (de)
ZA (1) ZA200203431B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US20050038048A1 (en) * 2001-10-29 2005-02-17 Ball Howard Ashley Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases
EP2305255B1 (de) * 2001-12-03 2012-08-22 Bayer HealthCare LLC Arylharnstoff-Verbindungen in Kombination mit anderen zytostatisch oder zytotoxisch wirksamen Stoffen zur Behandlungen menschlicher Krebserkrankungen
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
SI1509230T1 (sl) * 2002-06-05 2007-06-30 Cedars Sinai Medical Center Gefitinib (iressa) za zdravljenje raka
EP1664716A4 (de) * 2003-08-15 2008-08-13 Smithkline Beecham Corp Krebs-biomarker
BRPI0414532B1 (pt) 2003-09-19 2018-06-05 Astrazeneca Ab Composto derivado de quinazolina, processo para preparar 0 mesmo, composição farmaceutica, e, uso de um composto derivado de quinazolina
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
US7701341B2 (en) * 2004-09-01 2010-04-20 Microsoft Corporation Device service provider interface
EP3698807A1 (de) 2005-01-21 2020-08-26 Genentech, Inc. Fixe dosierung von her-antikörpern
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
EP1982718A4 (de) 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd Pharmazeutische zusammensetzung zur krebsbekämpfung
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MA33091B1 (fr) 2009-03-11 2012-03-01 Ardea Biosciences Inc Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
ES2519348T3 (es) 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
EP2655413B1 (de) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
RU2692773C2 (ru) 2012-11-30 2019-06-27 Ф.Хоффманн-Ля Рош Аг Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
ATE446955T1 (de) * 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
CA2223081C (en) * 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
AU4079999A (en) * 1998-05-15 1999-12-06 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
EP2059902B1 (de) 2006-08-28 2010-04-07 Koninklijke Philips Electronics N.V. Verfahren und vorrichtung zur bilderweiterung

Also Published As

Publication number Publication date
DK1272188T3 (da) 2007-01-29
EP1272188A2 (de) 2003-01-08
AU1155901A (en) 2001-05-14
KR20020064306A (ko) 2002-08-07
GB9925958D0 (en) 1999-12-29
DE60030889T2 (de) 2007-04-05
PT1272188E (pt) 2007-01-31
ZA200203431B (en) 2003-02-26
WO2001032155A2 (en) 2001-05-10
NO20022065L (no) 2002-06-24
JP2003513035A (ja) 2003-04-08
WO2001032155A3 (en) 2002-05-10
NO323206B1 (no) 2007-01-22
US7553815B1 (en) 2009-06-30
IL149176A0 (en) 2002-11-10
NZ518696A (en) 2004-12-24
CA2389411C (en) 2009-09-01
AU779190B2 (en) 2005-01-13
DE60030889D1 (de) 2006-11-02
CY1106285T1 (el) 2011-10-12
NO20022065D0 (no) 2002-04-30
KR100785359B1 (ko) 2007-12-18
CN1197577C (zh) 2005-04-20
ES2275556T3 (es) 2007-06-16
CA2389411A1 (en) 2001-05-10
CN1387437A (zh) 2002-12-25
BR0015194A (pt) 2002-06-18
EP1272188B1 (de) 2006-09-20
MXPA02004272A (es) 2003-08-20

Similar Documents

Publication Publication Date Title
DE60030889D1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
ATE362363T1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
DE60118889D1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
BR9910511A (pt) Tratamento de tumores humanos com radiação einibidores de tirosina cinases receptoras de fatorde crescimento
MY169308A (en) Treatment of tnf? related disorders
ATE316785T1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE404202T1 (de) Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE602004022285D1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE60309887D1 (de) Kombination von einem aromatasehemmer mit einem bisphosphonat
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
ATE381930T1 (de) Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
ATE382347T1 (de) Pharmazeutische zusammensetzung zur verwendung bei der behandlung von malignen erkrankungen, umfassend eine kombination aus bisphosphonaten, einem cox-2 inhibitor und einem taxol
MX2007006927A (es) Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272188

Country of ref document: EP

REN Ceased due to non-payment of the annual fee